C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 Degrader
C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 Degrader . (MENAFN - EIN Presswire) 
 
  In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108968687/C4-Therapeutics-Presents-Cemsidomide-Phase-1-Data-At-The-American-Society-For-Hematology-ASH-Annual-Meeting-That-Demonstrated-Potential-To-Become-Best-In-Class-IKZF13-Degrader
2024-12-08
rss
(MENAFN - EIN Presswire) 
 
  In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent ...
C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 Degrader